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ABSTRACT 
DETECTING MUTATIONS RELATED TO ANTIBIOTIC RESISTANCE IN 
PSEUDOMONAS AERUGINOSA 
by Neda Nemat-Gorgani 
Excessive use of broad-spectrum antibiotics in hospitals has led to the emergence 
of highly resistant strains of Pseudomonas aeruginosa. To reduce the selection pressure 
for resistance, it is important to determine the antibiotic-susceptibility pattern of bacteria 
so that hospital patients can be treated with more narrow-spectrum and target-specific 
antibiotics. This study describes the development of a technique for detecting point 
muations in the fluoroquinolone resistance-determining region of the gyrA and parC 
genes as well as the efflux regulatory genes mexR, mexZ, and mexOZ that are associated 
with fluoroquinolone and aminoglycoside resistance. The assay is based on a short 
DNA-sequencing method using multiplex-fast polymerase chain reaction (PCR) and 
Pyrosequencing™ for amplification and sequencing of the selected genes. Fifty-nine 
clinical isolates of P. aeruginosa were examined for mutations in the above-mentioned 
genes. Mutations related to antibiotic resistance were detected in codons 83 and 87 of 
gyrA and codon 126 of the mexR regulatory gene. Results of this study suggest 
Pyrosequencing™ as a substitute for traditional methods, as it provides a rapid and 
reliable technique for determining the antibiotic-resistance pattern of a given bacterial 
strain in < 1 h. 
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PREFACE 
This thesis is organized in three chapters. Chapter I presents a general 
introduction on Pseudomonas aeruginosa and its resistance to antibiotics and the aim of 
the research study. Chapter II describes the mechanisms of antibiotic resistance in P. 
aeruginosa. Chapter III includes the details of the study, prepared as a manuscript 
entitled "Detection of point mutations associated with antibiotic resistance in 
Pseudomonas aeruginosa" (submitted to the Journal of Microbiological Methods). 
The last part of the thesis is composed of appendixes, which provides additional 
details about the data collected. 
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CHAPTER I 
INTRODUCTION 
Pseudomonas aeruginosa is a notorious opportunistic pathogen and is isolated 
mostly from patients with urinary tract infections, wound infections, and severe burns. P. 
aeruginosa infection is also known to be a serious problem in patients hospitalized with 
cystic fibrosis, cancer, and burns. Half of these infections are fatal. P. aeruginosa has 
been considered a nosocomial pathogenic bacterium in a number of studies. What makes 
P. aeruginosa infections problematic is the bacterium's resistance to antibiotics and 
disinfectants (Lambert, 2002). Antibiotic and disinfectant resistance have been attributed 
to 1) intrinsic resistance to a wide variety of antimicrobial agents due to low membrane 
permeability, 2) genetic capacity to express a wide range of resistance mechanisms, 3) 
acquisition of resistance to antibiotics through chromosomal mutations, and 4) 
acquisition of resistance genes from other organisms via plasmids, bacteriophages, and/or 
transposons (Lambert, 2002). 
P. aeruginosa is an extremely adaptive organism. It can grow on a wide range of 
substrates and quickly responds to environmental alterations (Lambert, 2002). It has a 
large genome (6.26 Mbp encoding 5,567 genes) compared to other common human 
opportunistic pathogens such as Escherichia coli K12 (4.64 Mbp), Haemophilus influenzae 
(1.83 Mbp encoding 1,714 genes), and Staphylococcus aureus N315 (2.81 Mbp encoding 
2,594 genes) (Lambert, 2002). P. aeruginosa consequently possesses substantial 
additional genetic capacity compared to other bacteria. This capacity may confer its 
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extremely adaptive nature, including the capacity to develop resistance when antibiotics 
are employed extensively (Lambert, 2002). 
Mechanisms of resistance to antibiotics in P. aeruginosa are either based on non-
mutational intrinsic resistance or mutational acquired resistance. Fluoroquinolones and 
aminoglycosides are two important classes of antibiotics used in the treatment of 
Pseudomonas infections. Pseudomonas readily develops resistance to these agents, 
reducing the antibiotic effectiveness. 
In this study, we developed a DNA-based technique to determine the antibiotic-
resistance pattern of P. aeruginosa in a shorter period of time compared with traditional 
methods such as disk diffusion or agar dilution. We used multiplex polymerase chain 
reaction (PCR) and Sanger sequencing to find key mutations in the gyrA, mexR, parC, 
mexZ, and mexOZ genes of P. aeruginosa isolates exhibiting resistance to 
fluoroquinolones and aminoglycosides. Furthermore, Pyrosequencing™ was used as the 
ultimate method to detect specific point mutations in the above-mentioned genes. 
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CHAPTER II 
MECHANISMS OF ANTIBIOTIC RESISTANCE IN PSEUDOMONAS AERUGINOSA 
This section reviews the resistance of P. aeruginosa to antibiotics and 
antimicrobial agents based on non-mutational intrinsic resistance and mutational acquired 
resistance. 
1. Non-mutational intrinsic resistance 
P. aeruginosa has natural resistance to many antimicrobial agents. This is 
primarily due to active efflux systems that are present in all wild-type strains, its 
membrane permeability properties, and plasmid and chromosomal pMactamase genes 
(Aires et al., 1999, Giwercman et al., 1990, Lambert, 2002, Livermore, 2002). 
The most well-known efflux system that leads to intrinsic antibiotic resistance is 
the MexAB-oprM system. Efflux pumps are active transporters that are localized in the 
cytoplasmic membrane of all bacterial strains and reduce the antibiotic levels at the site 
of activity in the cell. Antibiotics are the most clinically important substrates of efflux 
systems. The MexAB-oprM efflux system is expressed constitutively in wild-type strains 
of P. aeruginosa and confers resistance to a broad range of drugs including quinolones, 
chloramphenicol, P-lactam, P-lactam inhibitors, trimetoprime, sulfamethoxasole, 
tetracycline, and novobiocin (Aires et al., 1999). 
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2. Mutational acquired resistance 
P. aeruginosa acquires resistance to antibiotics through chromosomal mutations. 
These mutations include 1) mutations in the regulatory genes for the drug efflux pump 
systems, 2) mutations in the target genes encoding DNA gyrase (gyrA) and 
topoisomerase IV (parC), 3) mutations causing cell wall impermeability due to loss of 
OprD, a porin that forms narrow transmembrane channels, 4) mutations causing 
alterations in penicillin-binding proteins, and 5) impulsive mutations in the regulatory 
genes for the bacteria's P-lactamase resulting in derepression of P-lactamase. 
2.1. Derepression of P-lactamase 
Chromosomally encoded p-lactamase is increasingly proven as a cause of 
resistance to novel p-lactam antibiotics (Giwercman et al., 1990). All strains of P. 
aeruginosa express a chromosomal AmpC P-lactamase. In the absence of P-lactam 
antibiotics, this enzyme is expressed at a very low basal level but can increase to much 
higher levels in the presence of the antibiotic. However, this stimulation is a transient 
response to p-lactam antibiotics. Strains displaying constant AmpC derepression produce 
higher amounts of p-lactamase, possibly due to the over expression resulting from 
spontaneous mutations in regulatory genes (Livermore, 2002). Antibiotics such as 
imipenem, benzylpenicillin, and cefoxilin are strong inducers, whereas newer P-lactam 
antibiotics such as piperacillin are weak inducers under in vitro conditions (Giwercman et 
al., 1990). 
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Three genes related to peptidoglycan recycling are implicated in ampC 
stimulation. These genes include ampD (encodes a cytosolic JV-acetyl-anhydromuramyl-
Z-alanine amidase and specifically hydrolyzes 1,6-anhydromuropeptide), ampR (encodes 
a transcriptional regulator of the LysR family), and ampG (functions as a permease for 
1,6-anhydromuropeptide, the signal molecule for stimulation of ampC expression, and 
encodes a transmembrane protein) (Langaee et al., 2000). Inactivation of AmpD results 
in cytoplasmic buildup of 1,6-anhydromuropeptide and finally constitutive over 
expression of AmpC (Langaee et al., 2000). In P. aeruginosa, three phenotypes of 
distorted AmpC expression have been related to p-lactam resistance, and two out of three 
have been related to mutations in the ampD gene (Langaee et al., 2000). AmpR and 
AmpD regulators also control the inducible expression of the ampC gene (Langaee et al., 
2000). 
Plasmid-encoded P-lactamases active against cephalosporins and penicillins may 
provide a mechanism for P-lactam resistance (Giwercman et al., 1990, Lambert, 2002). 
For newer stable P-lactam antibiotics, the rapid appearance of P-lactam resistance during 
drug therapy and frequent therapeutic failures related to the expansion of multiple 
resistances to P-lactam antibiotics are now common (Giwercman et al., 1990). 
2.2. Multidrug efflux pumps 
The combination of numerous resistance genes was first thought to be the 
exclusive cause of multiple antibiotic resistances in bacteria, each encoding resistance to 
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a separate drug. More recently, resistant phenotypes have been found to be due to the 
activity of drug efflux pumps (Nikaido, 1998). Several of these efflux pumps reveal 
broad ranges of specificity covering nearly all chemotherapeutic agents, inhibitors, 
detergents, and antibiotics (the exemption possibly being highly hydrophilic complexes). 
These efflux pumps work efficiently through their synergetic interaction with the outer 
membrane barrier in some Gram-negative bacteria, including P. aeruginosa (Nikaido, 
1998). 
Three protein components make up the multidrug efflux system: an outer 
membrane porin, an energy dependent pump positioned in the cytoplasmic membrane, 
and a linker protein which couples these two membrane components. This tripartite 
arrangement removes toxic molecules such as antibiotics that find their way into the 
cytoplasmic membrane, the periplasm, or the cytoplasm (Lambert, 2002). 
In P. aeruginosa four different efflux systems have been observed: MexAB-
oprM, MexXY-oprM, MexCD-oprJ, and MexEF-oprN. The pump proteins MexB and 
MexY are positioned in the cytoplasmic membrane, whereas MexA and MexX which are 
so called "membrane fusion" proteins are anchored in the inner membrane, but extend to 
the periplasm. Two of these pumps, MexXY-oprM and MexAB-oprM supply the 
intrinsic resistance of wild-type strains to antibiotics. MexXY-oprM is responsible for 
extrusion of aminoglycosides, whereas MexAB-oprM extrudes pMactams, quinolones, 
and a large range of disinfectants (Lambert, 2002). The genes for these systems exist in 
all strains of P. aeruginosa, but are not expressed in high amounts (Lambert, 2002). 
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MexAB-oprM may lead to elevated antibiotic resistance in clinical strains when it is 
expressed in high levels as a result of mutations that take place in the mexR regulatory 
gene of the bacteria (Aires et al., 1999). The two other efflux pump systems, MexCD-
oprJ and MexEF-oprN are not constitutively formed in the wild-type strains of P. 
aeruginosa. These efflux pumps are homologous to MexAB-oprM, and are more 
substrate-restricted than MexAB-oprM. They are capable of accommodating complexes 
as structurally diverse as trimethoprime, chloramphenicol, and quinolones. NficB and 
mexT (nficC) are regulatory genes for MexCD-oprJ and MexEF-oprN, respectively. 
Mutations that take place in these genes are also associated with higher levels of 
antibiotic resistance (Aires et al., 1999). 
MexY, homologous to AcrD in Escherichia coli, is related to a membrane fusion 
protein MexX and serves as a drug proton anti-porter. Elevated levels of expression of 
MexXY efflux system has been observed in few aminoglycoside resistant types of P. 
aeruginosa, and has been illustrated as a major source of aminoglycoside resistance in 
isolates collected from the lungs of CF patients (Islam et al., 2004). It has been suggested 
that MexXY efflux pump system shares the OprM channel with MexAB, since it does not 
have a gene for an outer membrane protein that should be located downstream of mexY. 
The expression of MexXY is under negative regulation by another protein called MexZ. 
This protein is encoded by a gene that is located 263 bp upstream of mexXand is 
transcribed divergently. MexZ is thought to have a DNA-binding domain at its N-
terminal that contains a helix-turn-helix motif. In wild-type P. aeruginosa isolates 
deletion of MexXY increases their susceptibility to antibiotics such as erythromycin, 
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tetracycline, and gentamycin. MexXY-oprM is also inducible by gentamycin and 
tetracyclin antibiotics and has the ability to pump out fluoroquinolones, macrolides, and 
carbapenems (Islam et al., 2004). 
2.5. Mutational impermeability 
In P. aeruginosa the outer membrane limits the rate of penetration of small 
hydrophilic molecules and at the same time excludes larger molecules. The outer 
membrane also serves as an important barrier to the penetration of antibiotics. P-lactams 
and quinolones are small hydrophilic molecules which can only pass the outer membrane 
through the aqueous channels supplied by porin proteins. Several different porins are 
formed in P. aeruginosa. OprF is one of the major porins that is present in all strains of 
P. aeruginosa. Although mutant strains lacking the OprF porin have been documented, 
lack of this porin has not been reported to have a significant effect on antibiotic resistance 
of the organism to any drugs, most probably because such strains have limited capability 
to take up hydrophilic compounds (Lambert, 2002). 
Resistance to imipenem and reduced susceptibility to meropenem is reported to be 
associated with loss of OprD porin. OprD is a porin which shapes narrow 
transmembrane channels and is only utilized by carbapenems but not other P-lactams. 
OprD is co-regulated with Mex-EF-oprN. Therefore, the njxC (mexT) mutants that are 
selected by antibiotics such as fluoroquinolones (but not carbapenems) have up-regulated 
MexEF-oprN and lower OprD levels. These mutants subsequently have abridged 
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susceptibility to meropenem and resistance to both imipenem and fluoroquinolones 
(Livermore, 2002). 
2.4. Alterations in penicillin-binding proteins 
In P. aeruginosa alterations in penicillin-binding proteins are also related to P-
lactam resistance. The efflux pump system adds only weakly to P-lactam resistance 
(caused by PBP mutations) most likely because the increased antibiotic buildup predicted 
in the deletion copies is still inadequate to overcome the lowered affinity of the PBP for 
p-lactams (Masuda et al., 2000). 
2.5. DNA gyrase and topoisomerase TV mutations 
The DNA gyrase is a holoenzyme which is a tetramer consisting of A and B 
subunits. These subunits are products of gyrA and gyrB, respectively (Kureishi et al., 
1994). The DNA gyrase enzyme is a type II DNA topoisomerase responsible for 
introducing negative superhelical coils into covalently attached DNA in a process that is 
ATP-dependent (Kureishi et al., 1994). It also functions in DNA decatenation, 
replication, and transcription regulation of some promoters that are supercoil sensitive 
(Kureishi et al., 1994). The A subunits are in charge of DNA reunion and breakage, and 
the B subunits are dedicated to ATP hydrolysis (Kureishi et al., 1994). DNA gyrase has 
been proven to be a suitable target for antibiotics (Kureishi et al., 1994). Quinolones 
such as ciprofloxacin and nalidixic acid inhibit the action of the A subunits while 
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antibiotics such as coumermycin Al and novobiocin are known to inhibit the action of B 
subunits (Kureishi et al., 1994). The glyeocinnamoylspermidine agent cinodine and 
microcin (an antibiotic peptide) have also been reported to inhibit the function of the 
DNA gyrase enzyme (Kureishi et al., 1994). 
In most countries fluoroquinolones are the only accessible antibiotics for oral 
treatment of infections caused by P. aeruginosa (Jalal et al., 2000). However, it easily 
becomes resistant to these antibiotics, rigorously constraining their effectiveness. 
Mutations in the target genes that encode DNA gyrase (gyrA) and topoisomerase IV 
(parC) are the main mechanisms of resistance to fluoroquinolones (Jalal et al., 2000). 
Mutational studies have shown that parC mutations in codon 80 (Ser—• Leu), and codon 
84 (Glu—>Lys) have been associated with higher fluoroquinolone resistance (Nakano et 
al., 1997). GyrA mutations in codon 83 (Thr—>Ile) and codon 87 (Asp—»Asn or 
Asp—»Tyr) are associated with elevated fluoroquinolone resistance (Yonezawa et al., 
1995). Multiple mutations in both parC and gyrA genes in codons 80, 83, 84, and 87 are 
linked to much more elevated resistance in P. aeruginosa (Mouneimne et al., 1999, 
Nakano etal., 1997.) 
A recent study on fluoroquinolone resistant P. aeruginosa (MI032) clinical 
isolates have shown that gyrA mutations with an additional mutation in the mexR 
regulatory gene leads to accelerated resistance. This signifies that antibiotic resistance 
associated with DNA gyrase in general corresponds to efflux and gyrA mutations (Jalal et 
al., 2000, Nakajima et al., 2002). 
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2.6. P. aeruginosa biofilms and resistance 
Creation of an alginate barrier is another resistance mechanism in P. aeroginosa. 
P. aeruginosa grows in microcolonies enclosed in an alginate barrier composed of 
various polysaccharides (Lambert, 2002). This kind of growth typifies biofilm (Lambert, 
2002). Notable resistance to antibiotics is common to all biofilms (Lambert, 2002). 
Although documented for many years, the complete biological events in bioflim 
formation and antibiotic resistance are not well understood. Physical segregation of the 
antibiotic and high bacterial concentration are factors that participate in the resistance of 
bacteria in biofilm (Lambert, 2002). In general, reactions to physiological alterations 
may arise in cells in the biofilm in which defensive mechanisms are provoked and key 
metabolic pathways are shut down. It is apparent that cells in the biofilm can alter their 
properties according to surrounding cells by sensing their presence (quorum sensing) 
(Lambert, 2002). The biofilm consists of a heterogeneous population of cells, including 
slow and fast growing cells. Some cells are resistant through production of efflux pumps 
and inactivating enzymes, whereas others are not (Lambert, 2002). Therefore, the 
general resistance relies on the interaction of the entire population, and therapies need to 
be aimed against a community that is multicellular (Lambert, 2002). 
2.7. Propositions for therapy 
Efflux and restricted permeability are essential properties of the organism and are 
crucial in developing resistant phenotypes to antibiotics as diverse as quinolones, p-
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lactams, and aminoglycosides. In other words, innate resistance results from the action of 
efflux systems and restricted permeability of the cell wall, and may be enhanced by 
elevated expression of special efflux pump systems (Lambert, 2002). 
In CF patients, the incidence of more specific mechanisms which engage alteration 
and inactivation in target molecules reflects the selective pressure due to reliance of these 
patients to these drugs. For example, expression of chromosomal (3-lactamase can be 
increased by spontaneous mutations in the chromosomal genes. These mutants are 
chosen under the stress of antibiotic treatment especially when monotherapy is used. 
Increased recognition of the role of efflux pumps in causing natural resistance to 
antibiotics has resulted in the search for efflux pump inhibitors which could serve as 
therapeutic adjuncts. Correspondingly, understanding of the multifaceted interaction in 
biofilm populations may ultimately lead to developing novel therapeutic approaches. 
However, P. aeruginosa has always adapted to antibiotic therapy. The threatening size of 
its genome and the present lack of information of the role of many of its genes will 
continue to be an important issue in developing novel therapies (Lambert, 2002). 
13 
REFERENCES 
Aires, J.R., Kohler, T., Nikaido, H., Plesiat, P., 1999. Involvement of an active efflux 
system in the natural resistance of Pseudomonas aeruginosa to aminoglycosides. 
Antimicrob Agents Chemother. 43, 2624-2628. 
Giwrcman, B., Lambert, P.A., Rosdahl, V.T., Shand, G.H., Hoiby, N., 1990. Rapid 
emergence of resistance in Pseudomonas aeruginosa in cystic fibrosis patients 
due to in-vivo selection of stable partially derepressed beta-lactamase producing 
strains. J Antimicrob Chemother. 26,247-259. 
Islam, S., Jalal, S., Wretlind, B., 2004. Expression of the MexXY efflux pump in 
amikacin-resistant isolates of Pseudomonas aeruginosa. Clin Microbiol Infect. 
10, 877-883. 
Jalal, S., Ciofu, O., Hoiby, N., Gotoh, N., Wretlind, B., 2000. Molecular mechanisms of 
fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic 
fibrosis patients. Antimicrob Agents Chemother. 44, 710-712. 
Kureishi, A., Diver, J.M., Beckthold, B., Schollaardt, T., Bryan, L.E., 1994. Cloning and 
nucleotide sequence of Pseudomonas aeruginosa DNA gyrase gyrA gene from 
strain PAOl and quinolone-resistant clinical isolates. Antimicrob Agents 
Chemother. 38,1944-1952. 
Lambert, P.A., 2002. Mechanisms of antibiotic resistance in Pseudomonas aeruginosa. J 
R Soc Med. 95 Suppl 41,22-26. 
Langaee, T.Y., Gagnon, L., Huletsky, A., 2000. Inactivation of the ampD gene in 
Pseudomonas aeruginosa leads to moderate-basal-level and hyperinducible 
AmpC beta-lactamase expression. Antimicrob Agents Chemother. 44, 583-589. 
Livermore, D.M., 2002. Multiple mechanisms of antimicrobial resistance in 
Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis. 34, 634-640. 
Masuda, N., Sakagawa, E., Ohya, S., Gotoh, N., Tsujimoto, H., Nishino, T., 2000. 
Contribution of the MexX-MexY-oprM efflux system to intrinsic resistance in 
Pseudomonas aeruginosa. Antimicrob Agents Chemother. 44, 2242-2246. 
Mouneimne, H., Robert, J., Jarlier, V., Cambau, E., 1999. Type II topoisomerase 
mutations in ciprofloxacin-resistant strains of Pseudomonas aeruginosa. 
Antimicrob Agents Chemother. 43, 62-66. 
14 
Nakajima, A., Sugimoto, Y., Yoneyama, H., Nakae, T., 2002. High-level fluoroquinolone 
resistance in Pseudomonas aeruginosa due to interplay of the MexAB-OprM 
efflux pump and the DNA gyrase mutation. Microbiol Immunol. 46, 391-395. 
Nakano, M., Deguchi, T., Kawamura, T., Yasuda, M., Kimura, M., Okano, Y., Kawada, 
Y., 1997. Mutations in the gyrA and parC genes in fluoroquinolone-resistant 
clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 41, 
2289-2291. 
Nikaido, H., 1998. Multiple antibiotic resistance and efflux. Curr Opin Microbiol. 1, 516-
523. 
Yonezawa, M., Takahata, M., Matsubara, N., Watanabe, Y., Narita, H., 1995. DNA 
gyrase gyrA mutations in quinolone-resistant clinical isolates of Pseudomonas 
aeruginosa. Antimicrob Agents Chemother. 39, 1970-1972. 
15 
CHAPTER III 
DETECTION OF POINT MUTATIONS ASSOCIATED WITH ANTIBIOTIC 
RESISTANCE IN PSEUDOMONAS AERUGINOSA 
Neda Gorganiabl, Scott Ahlbrand0'1, Andrew Patterson0 and Nader Pourmanda,d* 
a
 Stanford Genome Technology Center, Stanford University, Palo Alto, CA 94304, USA 
Department of Biological Sciences, San Jose State University, San Jose, CA 95192, USA 
c
 Stanford School of Medicine, Stanford University, Palo Alto, CA 94305, USA 
Biomolecular Engineering, University of California at Santa Cruz, Santa Cruz, CA 
95064, USA 
Key words: Pyrosequencing, Pseudomonas aeruginosa, antibiotic resistance 
* Corresponding author. Tel: +1 831 502 7315; fax: +1 831 459 4829. 
E-mail address: pourmand@soe.ucsc.edu (N. Pourmand). 
1
 These authors have equal contribution to this work. 
16 
ABSTRACT 
Excessive use of broad-spectrum antibiotics in hospitals has led to the emergence of 
highly resistant strains of Pseudomonas aeruginosa. To reduce the selection pressure for 
resistance, it is important to determine the antibiotic-susceptibility pattern of bacteria so 
that hospital patients can be treated with more narrow-spectrum and target-specific 
antibiotics. This study describes the development of a technique for detecting point 
muations in the fluoroquinolone resistance-determining region of the gyrA and par-C 
genes as well as the efflux regulatory genes mexR, mexZ, and mexOZ that are associated 
with fluoroquinolone and aminoglycoside resistance. The assay is based on a short 
DNA-sequencing method using multiplex-fast polymerase chain reaction (PCR) and 
Pyrosequencing™ for amplification and sequencing of the selected genes. Fifty-nine 
clinical isolates of P. aeruginosa were examined for mutations in the above-mentioned 
genes. Mutations related to antibiotic resistance were detected in codons 83 and 87 of 
gyrA and codon 126 of the mexR regulatory gene. Results of this study suggest 
Pyrosequencing™ as a substitute for traditional methods, as it provides a rapid and 
reliable technique for determining the antibiotic-resistance pattern of a given bacterial 
strain in < 1 h. 
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1. Introduction 
The emergence of drug-resistant bacteria occurs frequently in the Intensive Care 
Unit (ICU) involving both Gram-negative and Gram-positive organisms. This is a 
problem for critical care physicians because there are now several pathogens that can 
only be effectively treated with a limited number of antimicrobial agents, e.g. 
methicillin-resistant Staphylococcus aureus (MRSA), Enterococcus faecium, and Gram-
negative bacteria producing extended-spectrum P-lactamases (Kollef and Micek, 2005). 
Multidrug-resistant (MDR) bacterial infections are associated with increased 
mortality, length of hospital stay, and cost of care (Geissler et al., 2003). For example, in 
a study from a large tertiary-care teaching hospital in Boston, MA, the median length of 
stay and hospital charges were significantly greater for patients with MRSA compared 
with those with methicillin-sensitive S. aureus. 
Successful treatment of patients admitted to the ICU with nosocomial or 
community-acquired infections depends on adequate initial antibiotic use. A common 
strategy is to begin with broad-spectrum antibiotic therapy, and later to de-escalate 
antibiotic therapy based upon culture and sensitivity data. Initial broad-spectrum therapy 
is necessary until culture data are available to guide focused antibiotic administration. 
However, broad-spectrum antibiotics are a leading cause of the emergence of drug-
resistant bacteria (Nseir et al., 2005). 
Several strategies have been investigated as a means of reducing the emergence of 
MDR bacteria in the ICU. One such strategy is to employ only narrow-spectrum 
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antibiotics directed at pathogens identified using rapid bedside detection devices. This 
strategy requires technology capable of detecting pathogens within minutes of sample 
collection, pathogen identification and analysis of antibiotic resistance patterns, and 
detection of organisms that may reside in the intracellular compartment. 
One of the more common nosocomial pathogens is Pseudomonas aeruginosa 
(Sherertz and Sarubbi, 1983). Excessive use of broad-spectrum antibiotics has led to the 
emergence of highly resistant strains of P. aeruginosa that are a major threat to patients 
in the ICU. Adequate treatment of P. aeruginosa infections with modern antibiotics is 
difficult due to the intrinsic ability of the bacterium to adapt rapidly to new environments 
and acquire resistance to common therapies (Lambert, 2002, Livermore, 2002). 
Fluoroquinolones and aminoglycosides are two important classes of antibiotics 
used in the treatment of Pseudomonas infections. Fluoroquinolones are members of the 
quinolone family that act as bactericidal agents by inhibiting bacterial DNA gyrase and 
topoisomerase IV, thereby inhibiting DNA transcription and replication. DNA gyrase is 
typically the target in Gram-negative organisms, whereas topoisomerase IV is the target 
in Gram-positive organisms. Aminoglycosides are a separate class of antibiotics that 
bring about their bactericidal action by binding to the bacterial 30S ribosomal subunit, 
inhibiting the translocation of the peptidyl-tRNA from the A-site to the P-site, causing 
misreading of the mRNA and thus rendering the bacterium unable to synthesize proteins 
vital to its growth. Pseudomonas readily develops resistance to these agents, 
consequently reducing their utility. The main mechanisms of resistance are mutations in 
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the genes that encode DNA gyrase (gyrA) and topoisomerase IV (parC). Other 
mechanisms include mutations in the regulatory genes of the multidrug efflux pumps, 
mexAB-oprM and mexXY-oprAf (Jalal et al., 2000). The MexAB-oprM efflux system 
contributes to the natural resistance of bacteria to a wide range of antibiotics including 
fluoroquinolones, P -lactams, and P-lactamase inhibitors, whereas MexXY-oprM 
contributes to aminoglycoside resistance. High expression of MexAB-oprM and 
MexXY-oprM may confer high levels of resistance to clinical strains as a result of 
mutations occurring mainly in their regulatory genes mexR and mexZ (Aires et al., 1999, 
Islam et al., 2004). Another region related to aminoglycoside resistance is mexOZ, which 
is an intergenic region between the mexZ and mexX genes of P. aeruginosa (Islam et al., 
2004). 
In this study, we attempted to design a DNA-based technique for rapid 
determination of the antibiotic-resistance pattern of P. aeruginosa compared with 
traditional methods such as disk diffusion or agar dilution. Multiplex polymerase chain 
reaction (PCR) and Sanger sequencing were used to find key mutations in the gyrA, 
mexR, parC, mexZ, and mexOZ genes of P. aeruginosa isolates exhibiting resistance to 
fluoroquinolones and aminoglycosides, and Pyrosequencing™ was used as the ultimate 
sequencing method to detect specific point mutations in these genes. 
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2. Materials and methods 
2.1. Clinical isolates of P. aeruginosa 
Fifty-nine previously identified clinical isolates of P. aeruginosa were obtained 
from the Microbiology Laboratory at Stanford Hospital (Stanford, CA) to evaluate 
mutations involved in antibiotic resistance. These isolates were previously tested by the 
Kirby-Baur method for their susceptibility to fluoroquinolones and aminoglycosides. 
Samples were accordingly assigned to one of three groups, i.e. resistant, intermediate or 
susceptible to either fluoroquinolones or aminoglycosides. Fluoroquinolones and 
aminoglycosides used in the antibiotic susceptibility tests were ciprofioxacin/levofloxacin 
and tobramycin, respectively. Of the 59 clinical isolates, 12 were resistant, 6 were 
intermediate, and 41 were susceptible to ciprofloxacin, levofloxacin or both (Table 1), 
and 43 were susceptible, 4 were intermediate and 12 were resistant to tobramycin. 
2.2. DNA extraction and multiplex PCR 
DNA was extracted from the 59 clinical isolates of P. aeruginosa using the 
Qiagen Kit (Qiagen, Valencia, CA) according to the manufacturer's instructions and was 
used as the DNA template for multiplex/multiplex-fast PCR. Primers gyrA-1 (5'-
GTGTGCTTTATGCCATGAG-3') and gyrA-2 (5*-GGTTTCCTTTTCCAGGTC-3') were 
used to amplify 287 bp of the fluoroquinolone resistance-determining region of the gyrA 
gene. Primers parC-1 (5'-CATCGTCTACGCCATGAG-3') and parC-2 (5'-
AGCAGCACCTCGGAATAG-3') were used to amplify 267 bp of the fluoroquinolone 
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resistance-determining region ofparC. For the mexR regulatory gene, mexR-1 (51-
CTGGATCAACCACATTTACA -3') and mexR-2 (5'-
CTTCGAAAAGAATGTTCTTAAA-3') primers were used to amplify the whole 503-bp 
region of the gene. Primers for amplification of gyrA, parC, and mexR were designed 
with Primer 3 software (http://fokker.wi.mit.edu/primer3/input.htm), using known 
sequences available in GenBank with accession numbers L29417, AB003428, and 
U23763, respectively. The regulatory genes mexZ and mexOZ were amplified using 
primers from published data (Islam et al., 2004). All primers were synthesized by 
Integrated DNA Technologies (Coralville, IA). 
PCR amplification was performed in a 50 ul mixture containing IX Thermo-
Start™ Buffer (ABgene, Rockford, IL), 2.5 mM MgCk, 0.2 mM mix of deoxynucleotide 
triphosphates (Sigma-Aldrich, St Louis, MO), 10 pmole of each primer, 1U of Thermo-
Start DNA polymerase (ABgene), and 150 ng of the DNA template. Amplification of the 
target regions was performed in 35 cycles consisting of initial heat activation at 95 °C for 
15 min, denaturation at 95°C for 45 s, annealing at 51°C for 45 s, and elongation at 71°C 
for 1 min, with a final elongation at 71 °C for 7 min. The PCR products obtained from 
this step were used for Sanger sequencing. 
2.3. Sanger sequencing 
Dideoxy sequencing was performed using BigDye™ Terminator Chemistry v. 3.1 
(Applied Biosystems, Foster City, CA) according to the manufacturer's instructions, as 
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described previously (Gharizadeh et al., 2006). Forward and reverse primers for gyrA, 
parC, mexR, mexZ, and mexOZ (Section 2.2) were used as sequencing primers using the 
ABI 3730 Bioanalyzer (Applied Biosystems). 
2.4. Multiplex-fast PCR 
Two fluoroquinolone-resistant isolates with mutations both on gyrA and mexR 
were chosen for multiplex-fast PCR. The primers used for amplification of gyrA and 
mexR with the Veriti™ 96-Well Fast Thermal Cycler (Applied Biosystems) were 
identical to those used in the traditional PCR (see Section 2.2). Forward gyrA and 
reverse mexR primers were biotin-labelled for single-strand separation. Amplification of 
the selected regions was performed in a 20 ul mixture with 2.5 mM MgCk, 0.2 mM mix 
of deoxynucleotide triphosphates (Sigma-Aldrich), 10 pmole of each primer, 1U of 
AmpliTaq Gold (Applied Biosystems), and 150 ng of the DNA template. Multiplex-fast 
PCR was performed in 25 cycles as follows: initial heat activation at 95°C for 10 min, 
denaturation at 95°C for 1 s, annealing at 46°C for 15 s, elongation at 72°C for 15 s, and 
final elongation at 72°C for 30 s. PCR products obtained from this step were used for 
Pyrosequencing™. 
2.5. Sample preparation for Pyrosequencing™ 
Sample preparation for Pyrosequencing™ was performed according to the 
manufacturer's instructions and as described previously (Gharizadeh et al., 2005). 
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Single-stranded DNA amplicons were prepared semi-automatically, using a Vacuum Prep 
Tool and Vacuum Prep Worktable (Biotage, Uppsala, Sweeden). A 10 ul aliquot of 
biotinylated PCR products was immobilized onto 3 ul streptavidin-coated Sepharose™ 
High Performance Beads (Amersham Biosciences, Piscataway, NJ) by incubating at 
42°C and agitation at 1400 rpm for at least 15 min in Eppendorf Thermomixer R 
(Eppendorf AG, Hamburg, Germany). Double-stranded DNA immobilized on Sepharose 
beads was washed with 70% ethanol and denatured with 0.2 M NaOH. Unbound single-
stranded DNA was washed with 0.1 M TE buffer [0.1 M Tris HC1 (pH 7.6) containing 1 
mM ethylene diamine tetra-acetic acid (EDTA)]. All the steps were performed according 
to the manufacturer's instructions for the Vacuum Prep Station. The beads carrying 
single-stranded DNA amplicons were suspended in 12 ul of annealing buffer [20 mM 
Tris-acetate (pH 7.6), 2 mM Mg-acetate] containing 0.3 pmole sequencing primers. The 
single-stranded DNA was annealed to the sequencing primer at 92°C for 2 min followed 
by incubation for 5 min at room temperature. 
2.6. Pyrosequencing™ 
Pyrosequencing™ (Biotage) was performed according to the manufacturer's 
instructions as described previously (Gharizadeh et al., 2005). Single-stranded PCR 
products were sequenced using a PSQ™ HS 96A System (Biotage). Sequencing was 
preformed according to the manufacturer's instructions in a total volume of 12 ul using 
PSQ™ 96 Gold Kit (Biotage). 
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2.7. Cloning 
PCR amplicons of gyrA were cloned using the TOPO TA Cloning ® Kit 
(Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. Cloned 
bacterial cells were cultured on LB medium (containing 10 g Bacto tryptone, 5 g Bacto 
yeast extract and 10 g NaCl in 1 L of ddHiO) and incubated at 37°C. Isolated single 
colonies from overnight cultures were suspended in 10 ul of water and incubated at 95 °C 
for 10 min. Fragments harboring the gyrA regions were then amplified, using 10 pmol of 
forward biotinylated gyrA primer, 10 pmol of reverse vector primer, and 10 ul of the cell 
lysate containing the DNA template. Amplification of the cloned fragments was 
performed using the same conditions as in Section 2.2. 
3. Results 
Fifty-nine clinical isolates of P. aeruginosa were examined for the occurrence of 
mutations related to antibiotic resistance. Fragments of gyrA, parQ mexR, mexZ, and 
mexOZ genes were amplified using multiplex PCR, and the efficacy of the amplification 
was determined by gel electrophoresis. All fragments amplified adequately (data not 
shown). The PCR samples were then analyzed for detection of point mutations in the 
fluoroquinolone resistance-determining regions of gyrA and parC as well as the efflux 
pump regulatory genes mexR, mexZ, and mexOZ, using the Sanger sequencing method. 
To identify point mutations, sequences from clinical isolates were compared with that of 
wild-type P. aeruginosa PAOl. Results from the molecular analysis were compared with 
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the antibiotic-susceptibility profile of bacterial isolates to assess the correlation between 
mutations and resistance (Table 1). 
Table 1 
Correlation between fluoroquinolone (ciprofloxacin/levofloxacin) susceptibility of 59 P. 
aeruginosa clinical isolates and mutations in gyrA and mexR genes. 
Mutations in gyrA (codon) 
Asp->Asn(87) 
T h r ^ I l e ( 8 3 ) 
Asp->Tyr(87) 
Mutations in mexR 
(codon) 
Val - • Qu (126) 
Mutations in parC 
None 
Mutations in mexZ and 
mexOZ 
Highly variable 
The results showed that among the 12 fluoroquinolone-resistant isolates, 4 had a 
single mutation in gyrA, 4 had mutations both in gyrA and mexR and 4 had no mutations 
in the sequence areas examined (Table 1). Mutations in mexZ and mexOZ genes were 
highly variable within isolates, making it difficult to correlate a specific mutation with 
aminoglycoside resistance. Therefore, mexZ and mexOZ genes were not further 
evaluated using Pyrosequencing™. 
Common mutations in fluoroquinolone-resistant strains occurred in codons 83 and 
87 of the gyrA gene (Fig. 1). The nucleic acid alterations that occurred in these codons 
changed the amino acid profile from Thr to He and Asp to Asn (or Asp to Tyr), 
respectively, consistent with previous reports (Jalal et al., 2000, Nakano et al., 1997, 
Yonezawa et al., 1995). No mutations were found inparC. A novel mutation related to 
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fluoroquinolone resistance occurred in codon 126 of the mexR regulatory gene, changing 
amino acid Val to Glu was detected (Fig. 2; Table 2). 
Table 2 
Mutations in gyrA, mexR, parC, mexZ, and mexOZ genes leading to amino acid 
alterations. 
Fluoroquinolone susceptibility 
(no. of isolates) 
Resistant (12) 
Intermediate (6) 
Suscpetible(41) 
Mutations in gyrA 
only 
4 
1 
1 
Mutations in mexR 
only 
0 
1 
12 
Mutations in both 
gyrA and mexR 
4 
1 
1 
No mutations in 
gyrA or mexR 
4 
3 
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To confirm the mutations related to fluoroquinolone resistance by 
Pyrosequencing™, the PCR products amplified from all isolates were sequenced again 
using a pre-programmed nucleotide dispensation, sequencing a 20-bp region starting 1 
base upstream of the mutation site detected by the Sanger sequencing method. This pre-
programmed sequencing was much more rapid and took only 20 min. Nucleotide 
patterns of each isolate were compared with those of the wild-type P. aeruginosa PA01 
for parts of the gyrA and mexR genes encoding amino acids 83, 87 and 126, respectively. 
Absent or added sequence signal peaks were designated as mutations (Figs. 1 and 2). All 
mutations detected by Sanger sequencing were confirmed by the Pyrosequencing™ 
method. 
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Fig. 1. Pyrograms of the 20-bp sequence (amino acids 83-87) of the gyrA gene of P. 
aeruginosa obtained by the pre-programmed DNA-sequencing method: 
(a) the wild-type sequence of gyrA with no alterations; (b) nucleotide C —> A alteration in 
codon 83; and (c) nucleotide G —• A alteration in codon 87. Arrows show the location 
of point mutations in the signal peaks. 
One isolate showed two peaks in a single nucleotide position that was expected to 
be an absent peak or a peak representing either one of the existing nucleotides (A or C). 
Because bacteria are haploid (one set of each gene), we suspected that this sample was a 
mixed sample rather than a single isolate. Therefore, the sample was cloned using a TA 
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Cloning Kit. The cloned fragments were amplified and further analyzed by 
Pyrosequencing™. Pyrosequencing™ was performed using a five-cycle ACGT 
nucleotide order dispensation. From the Pyrosequencing™ results, one-half of the 
colonies showed no mutations and were considered as wild-type and one-half showed a 
mutation. This confirmed that the sample had been a mixture, i.e. was contaminated by a 
wild-type or a mutant of P. aeruginosa. Fig. 3 shows the sequencing results before and 
after isolation of the sample by cloning. 
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Fig. 2. Pyrograms of the 20-bp sequence of the mexR regulatory gene of P. aeruginosa 
(amino acids 126-128) obtained by the pre-programmed DNA-sequencing method: (a) 
the wild-type sequence of mexR with no alterations; and (b) nucleotide T —• A alteration 
in codon 126. Arrows show the location of point mutations in the signal peaks. 
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For amplification using multiplex-fast PCR, two fluoroquinolone-resistant isolates 
with mutations both on gyrA and mexR were chosen and sequenced by 
Pyrosequencing™. The results from the signal peaks were identical to the signal peaks 
obtained by sequencing the amplicons from the multiplex PCR (data not shown). 
Multiplex-fast PCR together with Pyrosequencing™ took < 1 h for detection of gyrA and 
mexR mutations. 
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Fig. 3. Pyrograms of the DNA sequence of gyrA for an isolate of P. aeruginosa, (a) 
Sequencing data before cloning and isolation. The two arrows indicate the presence of 
both A and C nucleotides in the sequence. The gyrA gene was cloned into a plasmid 
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vector, amplified by polymerase chain reaction (PCR) and sequenced by 
Pyrosequencing™ using a five- cycle ACGT dispensation, (b and c) pyrograms after 
isolation of the mixed DNA sample; ca. 50% of the cloned vectors harbored DNA from 
wild-type (c) and 50 % harbored DNA from a mutant of P. aeruginosa (b) (C —• A 
alteration). 
4. Discussion 
Fluoroquinolone and aminoglycoside resistance can lead to treatment failure in P. 
aeruginosa infections (Aires et al., 1999, Jalal et al., 2000). Known mutations 
responsible for resistance are found in the genes expressing DNA gyrase, and 
topoisomerase IV and in genes that regulate the expression of efflux pumps. These 
mutations interfere with binding of these antibiotics to the target sites of the DNA gyrase 
and topoisomerase IV, or lead to hyperextrusion of the drug by the bacterial efflux 
pumps. Because traditional microbiological culturing is time-consuming, empirical 
treatment is often started 18-24 h prior to definitive identification of the pathogen and 48-
h prior to knowledge of its susceptibility profile. To eradicate drug-resistant strains of P. 
aeruginosa, it is crucial to design a molecular technique to identify resistance rapidly so 
that these infections may be treated appropriately. 
Rapid and reliable methods are needed for the detection of resistant organisms, 
most of which can be identified through a limited number of mutations. Multiplex-fast 
PCR together with Pyrosequencing™ provides the advantage of requiring lower sample 
volumes, significantly reducing the cost of performing sequencing reactions. Multiplex-
fast PCR and DNA sequencing by Pyrosequencing™ using a pre-programmed 
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sequencing approach, as outlined here, takes < 1 h, compared to other amplification and 
sequencing methods that take up to 5 hours. 
Notably, all the mutations detected by the Sanger sequencing method were 
confirmed by the more efficient Pyrosequencing™ method. For gyrA, the main 
mutations found to be related to fluoroquinolone resistance were on codons 83 and 87, as 
previously reported (Jalal et al., 2000, Jalal and Wretlind, 1998, Nakano et al., 1997, 
Yonezawa et al., 1995). We discovered a mutation in codon 126 of the mexR regulatory 
gene, changing amino acid Val to Glu, which correlated with fluoroquinolone resistance. 
Almost all the clinical isolates in this study that had a single mutation in mexR were 
susceptible and did not show any drug resistance, indicating that a mexR mutation alone 
may not change the susceptibility of the bacterium but causes resistance when it co-
occurs with a mutation on the gyrA gene. The mutations found on gyrA and mexR were 
also found in susceptible isolates, and not all resistant isolates had mutations on these 
genes (Table 1). Our results show that detection of gyrA and mexR mutations does not 
always imply resistance to fluoroquinolones, but that acquiring these mutations increases 
the likelihood of resistance. These discrepancies suggest the existence of other additional 
molecular mechanisms for fluoroquinolone resistance. 
Pyrosequencing™ was also able to distinguish a mixed sample from other clinical 
isolates. The pyrogram shows the presence of both A and C nucleotides at a single spot 
location in part of the gyrA gene. This could only be explained by assuming that this 
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sample was mixed since bacteria are haploid. Pyrosequencing™ results after cloning the 
gyrA fragment confirmed this hypothesis. 
In conclusion, point mutations in clinical isolates associated with antibiotic 
resistance are rapidly and reliably detected by DNA-sequencing using Pyrosequencing™ 
and multiplex-fast PCR. With this novel approach, clinical isolates could be analyzed 
quickly at lower cost. The panel of mutations screened can be readily expanded to cover 
other known resistance determinants in P. aeruginosa, and to detect mutations involved 
in a variety of antibiotic resistance scenarios. Rapid and simple detection of resistance 
determinants at the genetic level could guide the choice of more appropriate antibiotics, 
and enable effective employment of narrow-spectrum antibiotics. Ultimately, more 
accurate diagnosis and treatment could lower the incidence of resistance, and improve 
outcomes for patients with severe bacterial infections. 
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GENERAL CONCLUSIONS 
Opportunistic P. aeruginosa infection is a major problem in medical care. The 
growing threat from resistant strains calls for development of accurate diagnostic 
methods and effective treatment strategies. Recent studies have focused on molecular 
mechanisms of antibiotic resistance and genetic parameters involved in development, 
acquisition, and spread of resistance genes. Reports have demonstrated several molecular 
mechanisms of antibiotic resistance. Understanding the distribution and combinations of 
genetic resistance mechanisms will contribute to identify potential targets for new 
antibiotics, and developing better diagnostic tools and treatment strategies to meet the 
challenges of P. aeruginosa infection. 
In this study, a new molecular approach using DNA-sequencing methods 
(Pyrosequencing™ and multiplex-fast PCR), clinical isolates of P. aeruginosa were 
analyzed quickly for point mutations leading to resistance to current antibiotics. The 
method described in this study, can be readily expanded to cover a variety of known 
resistance determinants in P. aeruginosa. This technique could also be used as a general 
approach for mutation detection in other microbial resistance studies. Rapid and simple 
determination of resistance determinants at the genetic level could guide the choice of 
more appropriate antibiotics, and enable the development of narrower spectrum 
antibiotics. Ultimately, more accurate diagnosis and treatment could lower the incidence 
of resistance, and improve outcomes for patients with severe bacterial infections. 
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In this study, we designed a molecular technique for rapid, easy, and cost-
effective diagnosis of antibiotic resistance in clinical isolates of P. aeruginosa that can 
have application in epidemiological studies, and developing and implementing strategies 
for infectious diseases. Further investigation on larger numbers of isolates collected from 
different medical centers will be required. These isolates should include resistant as well 
as susceptible strains with their relevant susceptibility profiles which could not be 
validated in this preliminary study. Epidemiological data indicating the patient's status 
and the type of infectious diseases not included in this study will be helpful in 
interpreting the results. 
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APPENDIXES 
APPENDIX A. SUMMARY OF DNA-SEQUENCING RESULTS 
Table 1A. GryA,parC, mexR mutations, and fluoroquinolone susceptibility of P. 
aeruginosa clinical isolates. 
Sample ID 
M583111 
M586966 
M587161 
M586030 
W607182 
M586970 
M581880 
M586981 
F598875 
T613503-1 
T613503-2 
T613898-2 
T614089-2 
F597588-1 
F597588-3 
F596760-3 
F596760-2 
T614204-2 
T614052-1 
T612031-1 
T612031-2 
T613324-3 
T613324-2 
T614084-1 
T614084-2 
H605658-1 
M595294-2 
gyrA Mutations 
none 
none 
none 
none 
none 
none 
none 
none 
none 
none 
none 
none 
none 
none 
none 
none 
none 
none 
none 
none 
none 
none 
none 
none 
none 
(87) Asp->Asn 
none 
parC Mutations 
none 
none 
none 
none 
none 
none 
none 
none 
none 
none 
none 
none 
none 
none 
none 
none 
none 
none 
none 
none 
none 
none 
none 
none 
none 
none 
none 
mexR Mutations 
none 
(126) Val-»Glu 
(126) Val-^Glu 
none 
none 
none 
none 
(79) Asn-^Ser 
(126) Val-^Glu 
none 
none 
none 
(132)Val-*Ala 
(126) Val-^Ghi 
none 
none 
(126) Val-^Glu 
none 
none 
none 
none 
none 
(126) Val-^Glu 
none 
none 
none 
none 
(126) Val-^Ghi 
fluoroquinolone 
Susceptibility 
susceptible 
susceptible 
susceptible 
susceptible 
susceptible 
susceptible 
susceptible 
susceptible 
susceptible 
susceptible 
susceptible 
susceptible 
susceptible 
susceptible 
susceptible 
susceptible 
susceptible 
susceptible 
susceptible 
susceptible 
susceptible 
susceptible 
susceptible 
susceptible 
intermediate 
susceptible 
susceptible 
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W618073 
F615319 
F618171 
X360656 
M628794 
H640 
W643857 
F644797 
H638643-3 
F35726-2 
H638643-2 
H638636 
F624989 
M674446-2 
M674446-1 
H682001-5 
F676239-6 
F676239-5 
M665266-1 
F660729-2 
H663398 
T682138-4 
M665266-2 
F660729-1 
(87) Asp->Tyr 
none 
none 
none 
none 
none 
none 
none 
(87) Asp->Tyr 
none 
(87) Asp->Tyr 
none 
none 
none 
none 
(83) Thr-»Ife 
none 
none 
(83) Thr-^Ile 
none 
(83) Thr-»Ife 
(83) Thr^Ile 
(83) Thr-*Ile 
none 
none 
none 
none 
none 
none 
none 
none 
none 
none 
none 
none 
none 
none 
none 
none 
none 
none 
none 
none 
none 
none 
none 
none 
none 
(132)Val->A]a 
(126) Val-^Gki 
none 
none 
(126) Val-^Gki 
none 
none 
(126) Val-^Ghi 
(126) Val-*Glu 
none 
(126) Val-^Glu 
none 
none 
(126)Val-»Glu 
none 
none 
(126) Val-^Glu 
none 
none 
(126) Val-»Glu 
none 
none 
(126) Val-^Ghi 
(126)Val-+Glu 
none 
susceptible 
susceptible 
susceptible 
susceptible 
susceptible 
susceptible 
susceptible 
intermidiate (levofloxacin) 
intermidiate (levofloxacin) 
susceptible 
resistant 
intermidiate (levofloxacin) 
susceptible 
resistant 
resistant 
intermediate 
intermediate 
susceptible 
resistant 
susceptible 
resistant 
resktant 
resistant 
susceptible 
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Table IB. MexZ and mexOZ mutations, and tobramycin susceptibility of P. aeruginosa 
clinical isolates. 
Sample ID 
M583111 
M586966 
M587161 
M586030 
W607182 
M586970 
M581880 
M586981 
F598875 
T613503-1 
T613503-2 
T613898-2 
T614089-2 
F597588-1 
F597588-3 
F596760-3 
F596760-2 
T614204-2 
T614052-1 
T612031-1 
T612031-2 
T613324-3 
T613324-2 
T614084-1 
T614084-2 
H605658-1 
M595294-2 
M647759 
W670409-2 
mexZ Mutations 
no amplification 
(138)Leu->-Arg 
(186) Asn—+ser 
no amplification 
none 
none 
none 
none 
no amplification 
none 
Insertion (frame shift) 
(95) Glu-^Stop 
none 
(138)Leu—Arg 
(186) Asn—•ser 
(58) Val->Ala 
Deletion (frame shift) 
Deletion (frame shift) 
none 
none 
Deletion (frame shift) 
(131)Lys—Arg 
(131)Lys->Stop 
(131)Lys^Stop 
Deletion (frame shift) 
none 
Deletion (frame shift) 
(191)Met->Arg 
(163)Leu->Pro 
none 
(46) Gry-»Cys 
Deletion (frame shift) 
mexOZ Mutations 
295, 459 bps 
295,459 bps 
244bp 
244 bp 
Insertion (frame shift) 
244, 358 bps 
244 bp 
199,229,268,415 
244bp 
244 bp 
244 bp 
244, 302 bps 
295,459 bps 
244 bp 
244 bp 
244, 274 bps 
244, 274 bps 
none 
244 bp 
none 
none 
244 bp 
244 bp 
244 bp 
244 bp 
244 bp 
244 bp 
244,201 bps 
244 bp 
Tobramycin Susceptibility 
susceptible 
susceptible 
susceptible 
susceptible 
susceptible 
susceptible 
susceptible 
susceptible 
susceptible 
susceptible 
susceptible 
susceptible 
susceptible 
susceptible 
susceptible 
susceptible 
susceptible 
susceptible 
susceptible 
susceptible 
susceptible 
susceptible 
susceptible 
intermediate 
susceptible 
susceptible 
resistant 
susceptible 
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W670409-3 
F660729 
H663398-3 
T660514 
F624989 
H649427 
W618073 
F615319 
F618171 
X360656 
M628794 
H640927 
W643857 
F644797 
H638643-3 
F35726-2 
H638643-2 
H638636 
F624989 
M674446-2 
M674446-1 
H682001-5 
F676239-6 
F676239-5 
M665266-1 
F660729-2 
H663398 
T682138-4 
M665266-2 
F660729-1 
Deletion (Same shift) 
Deletion (frame shift) 
none 
none 
Deletion (frame shift) 
none 
no amplification 
none 
none 
(138)Leu->Arg 
(186)Asn->Ser 
none 
Deletion and insertions 
(frame shift) 
Deletion (frame shift) 
none 
no alignment 
none 
(144)Ak->Val 
none 
Deletion (frame shift) 
none 
none 
(138)Leu—Arg 
(186) Asn-*Ser 
(62) Met-+Lys 
(62)Met-+Lys 
(138) Leu-*Arg 
(209)Asp->Gry 
none 
no alignment 
no alignment 
none 
244 bp 
no amplification 
244 bp 
244 bp 
295,459 bps 
244, 324 bps 
244 bp 
244 bp 
none 
295,459 bps 
244,453 bps 
none 
244, 358 bps 
244 bp 
244,277 bps 
244,489 bps 
244 bp 
244 bp 
295,459 bps 
244 bp 
244 bp 
295, 335,459 bps 
244,489 bps 
244,489 bps 
295,459 bps 
no amplification 
244 bp 
295,459 bps 
295,459 bps 
no ampHication 
susceptible 
resistant 
resisant 
resistant 
susceptible 
intermediate 
susceptible 
susceptible 
susceptible 
susceptible 
susceptible 
susceptible 
susceptible 
intermediate 
susceptible 
susceptible 
susceptible 
susceptible 
susceptible 
resistant 
resistant 
resistant 
resistant 
resistant 
intermediate 
susceptible 
resistant 
resisant 
resistant 
susceptible 
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APPENDIX B. AGAROSE GEL ELECTROPHORESIS RESULTS 
Low range 
ladder mexOZ 
Low range 
ladder mexZ 
P. aeruginosa mexOZ (382 bp) and mexZ (594bp) 
PCR product 
Figure 1A and IB. Agarose gel electrophoresis (1.5%) results of P. aeruginosa PCR 
products using mexOZ and mexZ primers. 
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Low range 
ladder gyrA parC mexR 
P. aeruginosa gyrA (287bp), parC (267bp), 
and mexR (503bp) PCR product 
Figure 2. Agarose gel electrophoresis (1.5%) result of P. aeruginosa PCR products 
using gyrA, parC, and mexR primers. 
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